BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study-Reference-Cited by-同舟云学术

BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study

Published:2023-08 Issue:37 Volume:41 Page:5461-5468
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Rosa Regis Goulart,Falavigna Maicon,Manfio Josélia Larger,de Araujo Cintia Laura Pereira,Cohen Mírian^ORCID,do Valle Barbosa Gynara Rezende Gonzalez,de Souza Ana Paula,Romeiro Silva Fernanda Kelly,Sganzerla Daniel,da Silva Mariana Motta Dias,Ferreira Diogo,de Oliveira Rodrigues Cristina,de Souza Emanuel Maltempi,de Oliveira Jaqueline Carvalho,Gradia Daniela Fiori,Brandalize Ana Paula Carneiro,Royer Carla Adriane,Luiz Rafael Messias,Kucharski Gabriela Almeida,Pedrotti Fernando,Valluri Srinivas Rao,Srivastava Amit^ORCID,Julião Viviane Wal,Melone Olga Chameh,Allen Kristen E.,Kyaw Moe H.,Spinardi Julia^ORCID,del Carmen Morales Castillo Graciela,McLaughlin John M.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference30 articles.

1. World Health Organization. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern [cited 2022 Jan 6]. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.

2. GISAID. Tracking of variants. [cited 2022 Jan 6]. https://www.gisaid.org/hcov19-variants/.

3. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa;Viana;Nature,2022

4. Increased risk of SARS-CoV-2 reinfection associated with emergence of omicron in South Africa;Pulliam;Science,2022

5. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination;Cheng;Nat Med,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness of original BNT162b2 mRNA COVID-19 against symptomatic Omicron infection among children 5–11 years of age in Brazil: A prospective test-negative design study;Immunology Letters;2024-10

2. Boosting COVID-19 protection: insights from a Brazilian population-based cohort;The Lancet Regional Health - Americas;2024-06